Trials / Completed
CompletedNCT00002197
A Study of 1592U89 in HIV-Infected Children
1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 250 (planned)
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 6 Months – 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
Detailed description
This is an open-label, non-randomized study. All patients will be treated with 1592U89. Additionally, since optimal therapy usually includes the combined use of 2 or more antiretroviral agents in advanced patients, other novel antiretroviral therapies may be accessed through commercial means or via compassionate use programs. NOTE: 1592U89 should not be administered as a single new agent added to a failing treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abacavir sulfate |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002197. Inclusion in this directory is not an endorsement.